Literature DB >> 26283615

Thirty-day mortality in ED patients with new onset atrial fibrillation and actively treated cancer.

Thomas Lardaro1, Wesley H Self1, Tyler W Barrett2.   

Abstract

OBJECTIVES: Studies suggest that inflammatory, autonomic, and coagulation alterations associated with cancer may increase incident atrial fibrillation (AF). New-onset AF is associated with increased mortality in other nonneoplastic disease processes. We investigated the association of active cancer with 30-day mortality in emergency department (ED) patients with new-onset AF.
METHODS: We conducted an analysis within an observational cohort study at a tertiary care hospital that included ED patients with new-onset AF. The exposure variable was presence of active cancer. We defined active cancer as the patient received chemotherapy, radiotherapy, or recent cancer-related surgery within 90 days of the ED visit. The primary outcome was 30-day mortality. Logistic regression was used to analyze the association between cancer status and 30-day mortality adjusting for patient age and sex.
RESULTS: During the 5.5-year study period, 420 patients with new-onset AF were included in our cohort, including 37 (8.8%) with active cancer. Patients with active cancer had no clinically relevant differences in their hemodynamic stability. Among the 37 patients with active cancer, 9 (24%) died within 30 days. Of the 383 patients without active cancer, 11 (3%) died within 30 days. After adjusting for age and sex, active cancer was an independent predictor of 30-day mortality, with an adjusted odds ratio of 10.8 (95% confidence interval, 3.8-31.1).
CONCLUSIONS: Among ED patients with new-onset AF, active cancer appears to be associated with 11-fold increased odds of 30-day mortality; new-onset AF may represent progressive organ dysfunction leading to an increased risk of short-term mortality in patients with cancer.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26283615      PMCID: PMC4581961          DOI: 10.1016/j.ajem.2015.07.033

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  20 in total

1.  A clinical prediction model to estimate risk for 30-day adverse events in emergency department patients with symptomatic atrial fibrillation.

Authors:  Tyler W Barrett; Amy R Martin; Alan B Storrow; Cathy A Jenkins; Frank E Harrell; Stephan Russ; Dan M Roden; Dawood Darbar
Journal:  Ann Emerg Med       Date:  2010-08-21       Impact factor: 5.721

2.  The AFFORD clinical decision aid to identify emergency department patients with atrial fibrillation at low risk for 30-day adverse events.

Authors:  Tyler W Barrett; Alan B Storrow; Cathy A Jenkins; Robert L Abraham; Dandan Liu; Karen F Miller; Kelly M Moser; Stephan Russ; Dan M Roden; Frank E Harrell; Dawood Darbar
Journal:  Am J Cardiol       Date:  2015-01-06       Impact factor: 2.778

3.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.

Authors:  A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal:  Eur Heart J       Date:  2012-08-24       Impact factor: 29.983

4.  Thirty-day and 1-year outcomes of emergency department patients with atrial fibrillation and no acute underlying medical cause.

Authors:  Frank Xavier Scheuermeyer; Eric Grafstein; Rob Stenstrom; Grant Innes; Claire Heslop; Jan MacPhee; Reza Pourvali; Brett Heilbron; Lorraine McGrath; Jim Christenson
Journal:  Ann Emerg Med       Date:  2012-06-26       Impact factor: 5.721

5.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Authors:  Nicole M Kuderer; David C Dale; Jeffrey Crawford; Leon E Cosler; Gary H Lyman
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

6.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.

Authors:  E J Benjamin; P A Wolf; R B D'Agostino; H Silbershatz; W B Kannel; D Levy
Journal:  Circulation       Date:  1998-09-08       Impact factor: 29.690

7.  Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis.

Authors:  Allan J Walkey; Renda Soylemez Wiener; Joanna M Ghobrial; Lesley H Curtis; Emelia J Benjamin
Journal:  JAMA       Date:  2011-11-13       Impact factor: 56.272

8.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

9.  Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.

Authors:  Vincent Caggiano; Richard V Weiss; Timothy S Rickert; Walter T Linde-Zwirble
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

Review 10.  Dilemmas in the management of atrial fibrillation in chronic kidney disease.

Authors:  Holger Reinecke; Eva Brand; Rolf Mesters; Wolf-Rüdiger Schäbitz; Marc Fisher; Hermann Pavenstädt; Günter Breithardt
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

View more
  2 in total

1.  Heart rate variability for rapid risk stratification of emergency patients with malignant disease.

Authors:  K Boehm; M Duckheim; L Mizera; P Groga-Bada; N Malek; F Kreth; M Gawaz; C S Zuern; C Eick
Journal:  Support Care Cancer       Date:  2018-04-12       Impact factor: 3.603

Review 2.  Atrial Fibrillation and Stroke Risk in Patients With Cancer: A Primer for Oncologists.

Authors:  Marc Sorigue; Milos D Miljkovic
Journal:  J Oncol Pract       Date:  2019-12       Impact factor: 3.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.